Sacubitril/Valsartan for CKD5 Stage Dialysis Patients With Heart Failure
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Hemodialysis or peritoneal dialysis CKD5 patients with heart failure were randomly divided
into Sacubitril/Valsartan and irbesartan treatment groups. Comparing the survival rates, the
cardiac function, renal function, blood pressure success rate, and adverse reactions of two
groups, to evaluate whether the efficacy and safety of Sacubitril/Valsartan in the treatment
of patients with CKD dialysis combined with heart failure is superior to that of irbesartan.